Articles tagged with: Velcade
News»
Yesterday, the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, was the busiest day of the meeting for people interested in multiple myeloma. Myeloma-related presentations filled the entire morning and afternoon, and sometimes there were even multiple relevant presentations going on simultaneously.
The morning presentations about therapies combining current myeloma drugs will be covered in this update. Morning presentations about potential new myeloma therapies were covered in an update published earlier today, and presentations from the rest of the day will be covered in …
News»
Results from a number of multiple myeloma studies were presented yesterday during the second day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego.
Predicting Response To Immunomodulatory Drugs
During an oral presentation and a poster presentation yesterday, researchers discussed the role of the protein cereblon in the treatment of myeloma. Results from one study (abstract) in myeloma cell lines suggested that cereblon plays a key role in whether multiple myeloma patients respond to the immunomodulatory drugs Revlimid (lenalidomide) and pomalidomide. Another study (abstract) …
News»
Results of a recent study show that newly diagnosed multiple myeloma patients initially treated with a combination of cyclophosphamide, Velcade, and dexamethasone have better response rates and less severe side effects than patients treated with Revlimid-dexamethasone or cyclophosphamide-Revlimid-dexamethasone.
The survival outcomes for the patients treated with cyclophosphamide, Velcade, and dexamethasone also are promising.
However, the difference in survival rates between the three treatment regimens is not statistically significant.
This is partly because "the numbers [of patients in the study] were too small to show differences in survival,” explained Dr. Craig Reeder of the …
NewsFlash »
Inhibition Of MAGE-C1/CT7 Increases Sensitivity Of Myeloma Cells To Velcade – Results of a recent Brazilian study show that inhibiting the MAGE-C1/CT7 gene in myeloma cells increases their sensitivity to Velcade (bortezomib). Specifically, researchers found that Velcade decreased the number of dividing myeloma cells by 48 percent when the cells were inhibited from activating the MAGE-C1/CT7 gene; in comparison, when the cells were allowed to activate the gene, Velcade decreased the number of dividing myeloma cells by between 9 percent and 13 percent. The researchers also observed an increased frequency of programmed cell death when inhibited myeloma cells were treated with Velcade. Based on these results, the study authors concluded that the MAGE-C1/CT7 gene protects myeloma cells against the anti-cancer effects of Velcade. They speculated that targeting this gene could be a strategy for future multiple myeloma therapies. For more information, please see the article in the journal PLoS ONE.
GO-Y030 And GO-Y078 Inhibit Myeloma Cell Growth – Results of a recent Japanese study indicate that the molecules GO-Y030 and GO-Y078 suppress the growth of myeloma cells by inhibiting signaling pathways within the cells. GO-Y030 and GO-Y078 are synthetic variants of curcumin, a substance found in the Indian spice turmeric. In this study, researchers found that GO-Y030 and GO-Y078 were 7 to 12 times more effective at suppressing the growth of myeloma cells than curcumin. Moreover, GO-Y030 and GO-Y078 were 6 to 15 times more effective at inhibiting signaling pathways in myeloma cells and 14 times more effective at suppressing production of interleukin-6, a protein responsible for myeloma cell growth. Based on these results, the study authors concluded that GO-Y030 and GO-Y078 are potential candidates for future anti-myeloma therapies. For more information, please see the article in the journal Anticancer Research (abstract).
LLS Web Cast: Making Cancer Treatment Decisions – The Leukemia & Lymphoma Society (LLS) will be hosting a web cast tomorrow at 1 p.m. EST about making cancer treatment decisions. Topics covered include questions patients should ask to make informed treatment decisions, benefits and risks of standard treatments, clinical trial design and participation, and financial considerations related to cancer treatment. Dr. Gail J. Roboz of Weill Medical College in New York and Beth Patterson of Mission Delivery in Hampton, VA will speak at the event. For more information about the event or to register, please visit the Leukemia & Lymphoma website.
Multiple Myeloma Educational Program – An educational program for multiple myeloma patients will be held on December 7 in St. Louis, MO. Multiple myeloma specialist Dr. Keith Stockerl-Goldstein will speak about treatment options for myeloma patients as well as answer patients’ questions. Multiple myeloma patient Karl V. will also speak about his experiences. Registration will begin at 6 p.m., and the program will start at 6:30 p.m. The event is sponsored by Millennium, the manufacturer of Velcade. For more information or to register, please call 1-866-508-6181.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News»
Results of a recent Greek study show that high levels of the protein sclerostin in the blood are associated with advanced disease and poor bone formation in multiple myeloma patients.
In addition, the results indicate that Velcade may be effective in reducing sclerostin levels in myeloma patients.
“Our study has shown that sclerostin is increased in myeloma patients, and together with the [laboratory] data presented at the last ASH meeting, suggests that sclerostin inhibits the function of [bone-building cells] in myeloma,” said Dr. Evangelos Terpos of the Alexandra General Hospital in Athens, …
News»
A group of French myeloma specialists recently published a review of treatment strategies for multiple myeloma patients who have relapsed or become resistant to previous therapies.
This Beacon article, the second in a two-part series, summarizes the review’s insights into issues that need to be considered when choosing among relapse treatment options
Part 1 summarizes the review’s perspectives on the use of novel agents in the treatment of relapsed and refractory myeloma.
According to the authors of the review, the goal at relapse is to select a treatment regimen that maximizes …
News»
A group of French myeloma specialists recently published a review of treatment strategies for multiple myeloma patients who have relapsed or become resistant to previous therapies.
This Beacon article, the first in a two-part series, summarizes the review's perspectives on the use of novel agents in the treatment of relapsed and refractory myeloma.
A second Beacon article will look at the review's insights into issues that need to be considered when choosing among relapse treatment options.
The authors of the recent review begin their discussion by noting how use of the …
